These findings align with the classical TME paradigm, where M1 macrophages and CD8+ T cells are associated with an enhanced anti-tumor immune response, whereas M2 macrophages contribute to tumor progression and immune suppression82. The gene discussed is CD8A; the disease is neoplasm.